Help Pharmacy Clinical Gaps & Limitations: What the Evidence Actually Shows

What Help Pharmacy Actually Is (and Is Not)

Help Pharmacy is a Houston-based 503B outsourcing facility, a federal designation created by the Drug Quality and Security Act of 2013. That category sits between a retail pharmacy and a drug manufacturer. Unlike 503A pharmacies, a 503B facility can produce large batches without patient-specific prescriptions and must follow Current Good Manufacturing Practice (cGMP) standards. The FDA inspects 503B facilities on a risk-tiered schedule.

"503B" does not mean FDA-approved. The distinction matters clinically. FDA approval requires phase-3 randomized controlled trials demonstrating efficacy and safety in thousands of patients. Help's products have never undergone that process. Prescribers ordering from Help are relying on extrapolated data from branded-drug trials conducted with different formulations, different excipients, and different delivery systems.

The 503B vs. 503A Distinction

A 503A pharmacy compounds for an individual patient after receiving a valid prescription. A 503B facility pre-produces batches and ships to practitioners and clinics. Help operates under the 503B model, which carries higher volume and therefore higher systemic risk if a batch fails quality testing. The FDA's 2024 inspection of Help resulted in a Form 483 with observations related to laboratory controls and batch-record documentation, a matter of public record on the FDA's website [1].

Why Patients Choose It

Help fills a real market gap. Branded semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have faced persistent supply shortages since 2022, and their list prices can exceed $1,000/month without insurance coverage. Help offered compounded semaglutide at roughly $150, $300/month during that shortage window. Access and affordability are legitimate problems. The clinical gaps discussed below are not arguments against affordability; they are information patients need before making a decision.

The Compounded GLP-1 Evidence Problem

The single largest clinical gap in Help's GLP-1 offering is the complete absence of randomized trial data on its specific formulations.

Every piece of efficacy data cited in telehealth marketing for compounded semaglutide traces back to trials conducted with Novo Nordisk's proprietary semaglutide formulation. STEP-1 (N=1,961) showed 14.9% mean weight loss at 68 weeks with subcutaneous semaglutide 2.4 mg versus 2.4% with placebo [2]. SURMOUNT-1 (N=2,539) showed 20.9% mean weight loss at 72 weeks with tirzepatide 15 mg versus 3.1% with placebo [3]. Neither trial used a compounded product. Applying those numbers to an Help formulation is, scientifically, an extrapolation.

The Salt-Form Issue

The FDA has specifically flagged this concern. In a January 2025 guidance update, FDA stated that compounders using semaglutide sodium, semaglutide acetate, or other salt forms are not compounding the same "active moiety" as Ozempic/Wegovy, which use semaglutide base [4]. Bioavailability differences between salt forms of peptide drugs are not trivial. For small-molecule drugs, the FDA's own guidance acknowledges that salt selection affects dissolution rate, absorption, and systemic exposure.

Help has publicly stated that some of its semaglutide products contain the base form. Verifying that claim requires access to the certificate of analysis (CoA) for each batch, which patients can request but rarely do.

Dosing Titration Without RCT Backing

The standard titration protocol for Wegovy is fixed by Novo Nordisk and validated in trial data: 0.25 mg weekly for 4 weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg. Help offers multiple vial concentrations and dose-flexibility that appeals to prescribers wanting to titrate aggressively. That flexibility is also a risk. None of the accelerated or modified titration schedules commonly used with compounded products have been tested in trials. Nausea and vomiting rates in STEP-1 at standard titration were already 44% and 24.5%, respectively [2]. Faster titration could produce higher rates.

The Regulatory Tightrope: Shortage List Removal

On March 31, 2025, the FDA removed injectable semaglutide from its drug shortage list [5]. That removal has direct legal implications. Under 503B rules, a facility may compound a product that is a copy of an approved drug only while that drug appears on the FDA shortage list or meets other narrow criteria. With semaglutide off the shortage list, large-scale compounding of semaglutide by 503B facilities became legally precarious. The FDA provided a wind-down period, but the long-term production of compounded semaglutide by Help or any other 503B facility now sits on uncertain legal ground.

Tirzepatide's shortage status has been more complicated. FDA removed injectable tirzepatide from the shortage list in February 2025, then paused enforcement after legal challenges from compounding industry groups [6]. As of this writing, litigation is ongoing and the enforcement posture could change within months.

What Happens to Patients Mid-Titration

A patient who starts compounded semaglutide at 0.25 mg and titrates to 1.7 mg over five months may face an abrupt supply disruption if Help ceases production. Switching from compounded to branded semaglutide at that point requires insurance coverage or out-of-pocket cost of $1,000+/month, a re-authorization process, and sometimes a step-down in dose. Prescribers should document this risk in the informed-consent conversation before initiation.

Hormone Therapy: Where Compounding Has Legitimate Uses and Real Risks

Help's HRT line is clinically distinct from its GLP-1 products. Compounded hormone therapy has a longer history and, in some clinical scenarios, a genuine rationale.

The Endocrine Society's 2020 clinical practice guideline states: "We recommend against the use of compounded hormones unless a patient has a documented allergy to ingredients in an FDA-approved product or requires a dose or route not commercially available." [7] That position reflects a specific, narrow indication, not a wholesale endorsement of compounded hormone products.

Potency Variability

The US Pharmacopeia (USP) chapters 795 and 797 set standards for compounding. But a 2017 analysis published in JAMA Internal Medicine found that 25 of 40 tested compounded hormone preparations (62.5%) failed at least one USP quality test, with potency deviations ranging from 67.5% to 268% of labeled dose [8]. Help is a 503B facility with more rigorous QC requirements than 503A pharmacies, but the published potency-variability data in the broader compounding sector is a legitimate concern that patients deserve to know.

Bioidentical Claims vs. Regulatory Reality

Help markets products as "bioidentical," a term that describes molecular structure (identical to endogenous hormone) but says nothing about safety or efficacy compared to FDA-approved bioidentical options. FDA-approved estradiol patches (Vivelle-Dot, Climara) and micronized progesterone (Prometrium) are themselves molecularly bioidentical to endogenous hormones, have pharmacokinetic data, and carry package-insert guidance backed by trial data. The North American Menopause Society's 2022 position statement notes that "the term 'bioidentical' is not a regulatory or scientific term and does not mean safer or more effective." [9]

Peptides: The Legal Gray Zone Help Operates In

Help offers a broad peptide catalog including BPC-157, TB-500 (thymosin beta-4), CJC-1295, Ipamorelin, and others. None of these peptides hold FDA approval for any human indication. They are not on the FDA's 503B-eligible bulk drug substance list [10]. Their sale for human use exists in a regulatory gray zone that the FDA has been progressively narrowing.

What the FDA Has Said

In 2023, FDA placed several peptides on its list of substances that may not be compounded because they are "demonstrably unsafe at any dose or have not been shown to be safe and effective." BPC-157 and TB-500 are under active review. Prescribers who order these compounds take on liability that is rarely disclosed in direct-to-consumer marketing.

Human trial data for these peptides is nearly absent. A 2022 systematic review found zero randomized controlled trials of BPC-157 in humans; all efficacy claims derive from rodent models [11]. Extrapolating rodent peptide pharmacology to human clinical outcomes is methodologically unsound.

Growth Hormone Secretagogues

CJC-1295 and Ipamorelin are growth hormone secretagogues frequently marketed for anti-aging, muscle gain, and fat loss. The FDA has not approved either compound. A 2019 paper in the Journal of the Endocrine Society noted that long-term GH axis stimulation carries theoretical risks including insulin resistance, fluid retention, and carpal tunnel syndrome even at sub-pharmacologic doses [12]. Trial data quantifying these risks in the specific combinations and doses Help produces do not exist.

Quality Control: What the FDA's Form 483 Means in Practice

The FDA's 2024 Form 483 issued to Help Pharmacy contained observations about laboratory controls. Form 483 observations are not violations; they are documented concerns that require a written response and corrective action plan. However, they signal areas where the facility's QC did not fully meet inspectional expectations.

For patients, the practical question is: can you independently verify that the vial you received contains what the label states? You can request a Certificate of Analysis for your specific lot number. A CoA from a reputable third-party lab (not the compounder's in-house lab) carries more weight. Help does provide CoAs, but third-party verification on the specific lot a patient receives is not standard practice in the 503B industry.

Help Pharmacy vs. Alternatives: A Direct Comparison

Compounded GLP-1 alternatives to Help include Hallandale Health, Strive Pharmacy, and various 503A pharmacies operating under individual prescriptions. None of these have better trial data; they share the fundamental evidence gap. The relevant comparators for clinical decision-making are the FDA-approved branded products.

When Branded Products Are Clearly Preferable

Patients with cardiovascular disease should use FDA-approved semaglutide when possible. The SELECT trial (N=17,604) showed subcutaneous semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with overweight/obesity and established CVD [13]. That cardiovascular benefit was demonstrated with Novo Nordisk's formulation. Whether a compounded version produces identical cardiovascular protection is unknown.

Patients with type 2 diabetes similarly have strong evidence for branded GLP-1 receptor agonists. The FDA label for Ozempic includes a cardiovascular outcomes indication based on the SUSTAIN-6 trial (N=3,297), which showed a 26% reduction in the primary MACE endpoint [14]. No compounded product carries that label indication.

When Compounding May Be a Reasonable Bridge

A patient who cannot afford branded semaglutide, does not qualify for manufacturer savings programs, and has obesity with metabolic risk may face a choice between a compounded product and no treatment at all. In that specific scenario, a compounded GLP-1 prescribed by a licensed clinician who monitors metabolic markers, liver function, and GI side effects is a reasonable clinical bridge, not a permanent solution. The key word is bridge.

What to Ask Before Ordering from Help Pharmacy

Patients and prescribers can close some of the clinical gaps through due diligence. Before starting any Help product, consider these questions:

• Request the Certificate of Analysis for the specific lot, sourced from an independent third-party lab.
• Confirm whether the semaglutide product uses the base form or a salt form, and get that in writing from the dispensing pharmacist.
• Ask the prescribing clinician to document the shortage-list status and legal basis for the prescription at the time of writing.
• Establish a monitoring schedule: fasting glucose, lipids, renal function, and body weight at baseline, 12 weeks, and 24 weeks.
• Have a transition plan. If Help stops producing a product due to regulatory action, know in advance what the branded alternative costs and whether your insurance covers it.

The FDA-approved route is not always accessible. But an honest informed-consent conversation about the gaps documented here should precede any compounded hormone or GLP-1 prescription. Prescribers who skip that conversation take on liability that courts have not been sympathetic about.

Patients already using Help's compounded semaglutide who are approaching the 2.4 mg maintenance dose should ask their clinician to begin the insurance prior-authorization process for branded Wegovy now, before any potential supply disruption forces an unplanned transition.